Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to -$207.0 million.

  • Madrigal Pharmaceuticals' Cash from Investing Activities fell 227.53% to -$207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 9265.83%. This contributed to the annual value of -$274.4 million for FY2024, which is 4539.8% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Cash from Investing Activities of -$207.0 million as of Q3 2025, which was down 227.53% from $47.9 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Cash from Investing Activities ranged from a high of $163.9 million in Q1 2025 and a low of -$362.1 million during Q4 2023
  • Its 5-year average for Cash from Investing Activities is -$30.0 million, with a median of $15.6 million in 2021.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Cash from Investing Activities skyrocketed by 42603.17% in 2021 and then crashed by 317165.06% in 2024.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Cash from Investing Activities stood at $15.6 million in 2021, then surged by 324.39% to $66.4 million in 2022, then crashed by 645.47% to -$362.1 million in 2023, then skyrocketed by 86.76% to -$47.9 million in 2024, then plummeted by 331.69% to -$207.0 million in 2025.
  • Its Cash from Investing Activities stands at -$207.0 million for Q3 2025, versus $47.9 million for Q2 2025 and $163.9 million for Q1 2025.